文献速递消化道肿瘤放疗姑息放疗与转移瘤

高生物有效剂量姑息放疗可能改善肝癌合并癌栓患者的长期预后:一项回顾性研究

High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study.
PubMed 文献 · Radiat Oncol · 2017-05-31

中位随访24个月,1、3、5年OS率分别为77.6%、37.6%、18.8%。多因素分析显示性别、BED、Child-Pugh分级、ECOG及癌栓类型是OS的预后因素;高BED组中位OS优于低BED组(42个月 vs. 19个月,P=0.016)。

要点

  • 性别、BED、ECOG、Child-Pugh分级和癌栓类型是HCC合并癌栓患者OS的独立预后因素。
  • 癌栓类型从I到IV级,生存率呈逐步下降趋势。
  • 高BED姑息放疗组中位OS较低BED组更长(42个月 vs. 19个月,P=0.016)。

核心结论

  • 性别、BED、ECOG体能状态、Child-Pugh分级和癌栓类型似乎影响HCC合并癌栓患者的总生存。
  • 高BED姑息放疗可能改善HCC合并癌栓患者的长期结局。

研究设计与样本

  • 分析年龄、性别、临床特征、实验室检查、Child-Pugh分级、ECOG、癌栓类型、放疗方式、BED及主要治疗方式与OS的关系。
  • 使用SPSS version 19.0进行统计分析。

主要发现

  • 中位随访24个月(范围6-90个月),1年、3年、5年OS率分别为77.6%、37.6%、18.8%。
  • 单因素分析中,性别(P<0.001)、放疗方式(P=0.001)、BED(P=0.016)、癌栓类型(P=0.003)、Child-Pugh分级(P<0.001)、ECOG(P<0.001)和总胆红素(P=0.039)与OS相关。
  • 多因素分析中,OS的预后因素为性别(P<0.001)、BED(P=0.044)、Child-Pugh分级(P=0.020)、ECOG(P=0.004)和癌栓类型(P=0.001)。
  • 高BED组中位OS为42个月,低BED组为19个月(P=0.016)。
  • 癌栓类型从I到IV级,生存率呈逐步下降趋势。

临床怎么用

  • 对于HCC合并癌栓患者,可考虑采用高BED的姑息放疗以可能改善长期生存。
  • 评估预后时应综合考虑性别、BED、ECOG、Child-Pugh分级和癌栓类型。

局限性

  • 高BED与低BED的具体剂量阈值未在摘要中明确报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to highlight the type of tumor thrombus and identify the prognostic factors influencing the long-term survival outcomes in patients with hepatocellular carcinoma (HCC) having a tumor thrombus. A tumor thrombus in HCC is associated with poor prognosis. METHODS: Eighty patients diagnosed with HCC having a tumor thrombus between May 2006 and April 2014 were enrolled in this study. Age, gender, clinical characteristics, laboratory findings, Child-Pugh classification, performance status (ECOG), types of tumor thrombi, radiotherapy method, biologically effective dose (BED), and primary treatment method were analyzed to identify the prognostic factors associated with the overall survival (OS) rates. Statistical analyses were performed using SPSS version 19.0. RESULTS: The median follow-up duration was 24 months (range 6-90). The 1-, 3-, and 5-year OS rates of the patients were 77.6%, 37.6%, and 18.8%, respectively. On univariate analysis, gender, radiotherapy method, BED, types of tumor thrombi, Child-Pugh classification, ECOG, and total bilirubin were associated with OS (P < 0.001, P = 0.001, P = 0.016, P = 0.003, P < 0.001, P < 0.001, P = 0.039, respectively). The prognostic factors for OS in multi-variate analyses were gender (P < 0.001), BED (P = 0.044), Child Pugh classification (P = 0.020), performance status (ECOG) (P = 0.004), and types of tumor thrombi (P = 0.001). The median OS for the high-BED group was better than that for the low-BED groups (42 months vs. 19 months, P = 0.016). CONCLUSIONS: Gender, BED, performance status (ECOG), Child-Pugh classification, and types of tumor thrombi seemed to affect OS, and a stepwise decrease in survival was observed with the types of tumor thrombi ranging from I to IV. High-BED palliative radiotherapy might improve the long-term outcomes for patients with HCC having a tumor thrombus.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kong XQ, Dong YP, Wu JX, et al. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol. 2017. PMID: 28569169. doi:10.1186/s13014-017-0831-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。